Description
Product details
RAPIGLINIDE VOG 0.5 Repaglinide (0.5mg), Voglibose (0.3mg) Introduction: In the endeavor to manage diabetes effectively, the combination of medications with complementary mechanisms of action has gained prominence. Repaglinide and voglibose represent two such agents that target different aspects of glucose regulation. RAPIGLINIDE VOG 0.5 combines repaglinide (0.5mg) and voglibose (0.3mg) to provide comprehensive glycemic control. This article explores the features, efficacy, safety profile, and clinical implications of RAPIGLINIDE VOG 0.5 in diabetes management. Understanding Repaglinide and Voglibose: Repaglinide is a rapid-acting insulin secretagogue that stimulates insulin release from pancreatic beta cells, particularly after meals, thereby lowering blood glucose levels. Voglibose, on the other hand, is an alpha-glucosidase inhibitor that delays carbohydrate digestion and absorption in the intestine, leading to reduced postprandial glucose spikes. By targeting different pathways, repaglinide and voglibose complement each other to achieve optimal glycemic control. Key Features of RAPIGLINIDE VOG 0.5: RAPIGLINIDE VOG 0.5 is a fixed-dose combination tablet containing repaglinide (0.5mg) and voglibose (0.3mg). This standardized formulation offers the convenience of combining two effective antidiabetic agents in a single tablet, simplifying medication regimens and enhancing patient adherence. The combination of repaglinide and voglibose provides a synergistic effect, allowing for better control of both fasting and postprandial hyperglycemia. Efficacy in Glycemic Control: Clinical studies have demonstrated the efficacy of RAPIGLINIDE VOG 0.5 in improving glycemic control in patients with type 2 diabetes mellitus (T2DM). The combination of repaglinide and voglibose has been shown to reduce hemoglobin A1c (HbA1c) levels, fasting plasma glucose, and postprandial glucose excursions, leading to improvements in overall glucose regulation. Additionally, the rapid onset of action of repaglinide and the sustained effect of voglibose contribute to better glycemic control throughout the day. For further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 https://www.sterisonline.com/product/rapiglinide-vog-0-5-134238
